Because routinely screening newborns for cystic fibrosis leads to early diagnosis and means treatment can begin immediately.

ELITech Biomedical Systems is the acknowledged world leader for the laboratory diagnosis of cystic fibrosis with our proven Macroduct Sweat Collection System for stimulation and collection of sweat and our Sweat-Chek (total electrolyte analysis) or Chloro-Chek (Chloride titration) analyzers.

When considering a potential laboratory diagnosis of cystic fibrosis, a physician still relies heavily upon the results of the sweat test, which is capable of producing an unequivocal, quantitative result to corroborate clinical observations. The Macroduct System provides the most accurate and simple sweat test system available.

ELITech’s peerless scientific and engineering expertise has also produced Nanoduct, the completely integrated and miniaturized sweat analysis system for patients of any age.

The Nanoduct patented in-situ stimulation and analysis provide clinicians with the earliest possible laboratory diagnosis of cystic fibrosis, enabling doctors to intervene and treat this disease in the earliest days of life.

The Neonatal screening or Newborn Screening is a preventive pediatric screening service provided to all the neonates to assess the possibility of genetic disorders in the area of "Inborn Errors of Metabolism".

These errors, which are not harmful now, have all the potential to cause permanent neurological, cognitive, tactile and physical damage in the child. If such errors are detected in this newborn baby screening, they can be treated easily.

Trivitron provides a wide range Newborn Screening instruments, including Modular & Fully Automated NBS Instrumentation, manual & automated equipment and reagent kits.

Trivitron's Diagnostic division Labsystems Diagnostics OY occupies the second place in the world when it comes to New Born Screening Technology.